<DOC>
	<DOCNO>NCT00377715</DOCNO>
	<brief_summary>This study evaluate safety potential benefit Dimebon compare placebo patient mild moderate Alzheimer 's Disease .</brief_summary>
	<brief_title>Double-blind , Placebo-controlled Study Oral Dimebon Subjects With Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>1 . Males female great equal 50 year age . 2 . Diagnosis Alzheimer 's Disease accord Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIV TR ) Mini Mental State Exam 10 24 , inclusive Modified Hachinski Ischemia Score less equal 4 . 3 . Brain imaging MRI and/or CT within one year enrollment . 4 . Subjects must guardian caregiver assist subject least 5 day per week ( least 3 hours/day ) . 5 . Subjects must able cooperate drug administration ( include ability ingest oral medication ) study procedure abide study restriction . 6 . Subjects must least 6 year prior education previously ( preAlzheimer 's condition ) capable reading , write communicate effectively others . 7 . Subjects must willing able give inform consent mentally competent legal representative authorize provide informed consent behalf . 8 . Residence assist care facility allow subject living independently . 1 . Major structural brain disease 2 . Major medical illness unstable medical condition within 6 month screen may interfere subject 's ability comply study procedure abide study restriction . 3 . Residence nursing home assist care facility provide subject 24hour care supervision . 4 . Women pregnant , nursing , childbearing potential use medically accept , highly effective method birth control . 5 . Active alcohol dependence drug abuse . 6 . Use following medication within 60 day prior enrollment : cognition enhance agent , narcotic analgesic , low potency neuroleptic , antihypertensive agent frequent Central Nervous System ( CNS ) side effect , antiParkinsonian medication , medication central anticholinergic activity , medication epilepsy , lithium . 7 . Participation investigational drug device study within 30 day prior study entry , 60 day prior study entry investigational drug study involve therapy Alzheimer 's Disease .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Dimebon , Alzheimer 's Disease , Alzheimer 's Disease Assessment Scale-cognitive subscale ( ADAS-cog )</keyword>
</DOC>